Circulating microRNAs as stable blood-based markers for cancer detection.

Publication Type:

Journal Article


Proceedings of the National Academy of Sciences of the United States of America, Volume 105, Issue 30, p.10513-8 (2008)


2008, Animals, Cell Processing Core Facility, Center-Authored Paper, Clinical Research Division, Cloning, Molecular, Comparative Medicine Core Facility, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genomics Core Facility, Human Biology Division, Humans, Male, MICE, MICRORNAS, Neoplasm Transplantation, Neoplasms, Prostatic Neoplasms, Public Health Sciences Division, Ribonucleases, RNA, Neoplasm, Scientific Imaging Core Facility, Sensitivity and Specificity, Shared Resources, Specimen Processing Core Facility, Tumor Markers, Biological


Improved approaches for the detection of common epithelial malignancies are urgently needed to reduce the worldwide morbidity and mortality caused by cancer. MicroRNAs (miRNAs) are small ( approximately 22 nt) regulatory RNAs that are frequently dysregulated in cancer and have shown promise as tissue-based markers for cancer classification and prognostication. We show here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity. miRNAs originating from human prostate cancer xenografts enter the circulation, are readily measured in plasma, and can robustly distinguish xenografted mice from controls. This concept extends to cancer in humans, where serum levels of miR-141 (a miRNA expressed in prostate cancer) can distinguish patients with prostate cancer from healthy controls. Our results establish the measurement of tumor-derived miRNAs in serum or plasma as an important approach for the blood-based detection of human cancer.